India’s Hetero pulls heart drug from U.S. amid cancer risk probes


MUMBAI (Reuters) – A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator’s website said, amid a wider probe into cancer risks associated with the drug.

At least a dozen companies around the world have pulled specific batches of valsartan from the market since early July, when regulators said valsartan made by the Chinese supplier Zhejiang Huahai Pharmaceuticals had been found to contain a probable human carcinogen, N-nitrosodimethylamine (NDMA).

The notice from the U.S. Food and…



Read More Here

Be the first to comment on "India’s Hetero pulls heart drug from U.S. amid cancer risk probes"

Leave a comment

Your email address will not be published.


*